Hat jemand die Q-Zahlen v. Immunex??? - 500 Beiträge pro Seite

[proteindesigner]

Vielen Dank im voraus!

p.d.

[ricox]

SEATTLE, Oct 18, 2000 /PRNewswire via COMTEX/ -- Immunex Corporation (Nasdaq:IMNX) today reported net income of $31.5 million, or 6 cents per share, on total revenue of $219.0 million for the third quarter of 2000. These results compare to a net income of $21.0 million, or 4 cents per share, on revenues of $152.4 million reported in the third quarter of 1999. Revenues last year included a $10 million one-time scheduled payment related to a product. Total product sales were up 56 percent over third quarter 1999 to $217.2 million for the third quarter of 2000. Each of the company`s lead marketed products, ENBREL(R)(etanercept), LEUKINE(R) (sargramostim) and NOVANTRONE(R) (mitoxantrone for injection concentrate) hit record sales this quarter.

For the first nine months of 2000, the company reported net income of $105.2 million, or 19 cents per share, compared to a net income of $28.1 million, or 5 cents per share, for the first nine months of 1999. Revenues for the first nine months of 2000 were $611.2 million, up 61 percent over the same period last year.

"Immunex has hit the mark operationally," said Ed Fritzky, chairman and chief executive officer. "Consistently growing product sales and strong positive cash flow from operations have built a strong financial base for the company. We are very well positioned with a diverse product pipeline to expand and capitalize on multiple opportunities for future growth. The new FDA approval for NOVANTRONE for worsening forms of multiple sclerosis is the latest example of executing our strategy for growth."

Sales of ENBREL totaled $172.1 million for the third quarter, up 69 percent compared to sales in the third quarter of 1999. This marks the seventh straight quarter of plus-ten percent growth. Sales of ENBREL for the first nine months of 2000 were $458.3 million, up more than 84 percent compared to sales of $248.6 million during the same period last year.

Sales of the company`s specialty therapeutics products, including LEUKINE and NOVANTRONE, were up 24 percent to $44.8 million for the third quarter of 2000, compared to $36.0 million for the third quarter of 1999. Sales of LEUKINE grew 18 percent over the second quarter of 2000 to an historic quarterly high of $24.0 million. Specialty therapeutics sales for the first nine months of 2000 were $119.9 million compared to $108.5 million during the same period last year.

Total operating expenses for the third quarter of 2000 were $198.3 million, an increase from $130.1 million in the third quarter of 1999. Increased expenses reflect higher costs of product sales, which is a function of growing sales volume, and sales and marketing costs associated with ENBREL. Selling, general and administrative expenses were $88.8 million in the third quarter of 2000, compared to $56.9 million in the third quarter of 1999 in part due to profit sharing payments to co-promotion partner Wyeth-Ayerst for ENBREL. Wyeth-Ayerst is the pharmaceutical division of American Home Products.

Research and development investments in the third quarter of 2000 were $44.2 million, compared to $31.1 million in the third quarter of 1999.

"On the research front, this year we have invested to advance TRAIL/Apo2 Ligand and IL-1 receptor type II toward clinical trials, and we have significantly expanded our discovery efforts with a number of strategic collaborations," said Doug Williams, executive vice president and chief technology officer. "We have initiated programs in genomics with Celera, in therapeutic monoclonal antibodies with Abgenix and Urocor, and in chemistry with Array Biopharma and Oxford Asymmetry. In addition, the completion and staffing of our new process sciences facility will pave the way for moving more molecules to the clinical stage faster."

Cash flow from operations was $168.2 million for the nine months ended September 30, 2000. Cash and short-term investments totaled $817.7 million as of September 30, 2000.

Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovations.

American Home Products Corporation owns a majority interest in Immunex. AHP is one of the world`s largest research-based pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of prescription drugs, including biotechnological and vaccine products, animal health care products and over-the-counter medications.

NOTE: This news release contains forward-looking statements that involve risks and uncertainties, including risks associated with clinical development, regulatory approvals, our reliance on third-party manufacturers, product commercialization and other risks described from time to time in the SEC reports filed by Immunex, including the most recently filed Form 10-Q. An electronic version of this news release -- as well as additional information about Immunex of interest to investors, customers, future employees and patients -- is available on the Immunex home page at www.immunex.com.







Also das war wohl schlechter als erwünscht. Biotechs sollten die Erwartungen übertreffen, sonst sind alle enttäuscht.
Außerdem: Immunex nachbörslich -2 3/16$ = -4,7%

[proteindesigner]

warum soll das ergebnis schlechter sein als erwartet?
ich kann zumindest auf den ersten blick nichts negatives erkennen.

der nachbörsliche verlust v. 4.7.% ist,
1)sowieso momentan obligatorisch(s.ariba)
2)wohl auf eine jetzt angekündigte kapitalerhöhung zurückzuführen

bis bald,

p.d.